Results 191 to 200 of about 50,811 (294)

MITF Gain‐of‐Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Prostate cancer is the most common non‐cutaneous malignancy in men and remains a leading cause of cancer‐related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN.
Paul J. Pecorin, Nyembezi Dhliwayo, Matthew Demetrious, Ludimila Cavalcante, Veronica Rodriguez‐Bravo, Josep Domingo‐Domenech, Thomas Westbrook   +6 more
wiley   +1 more source

Ivonescimab monotherapy in an elderly patient with EGFR-TKI-resistant advanced lung adenocarcinoma and pericardial effusion: a case report and literature review. [PDF]

Front Immunol
Zhu C, Yu H, Gu Y, Jiang T.
europepmc   +1 more source

Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus‐Associated Disorders

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Kaposi sarcoma herpes virus (KSHV) is associated with multiple clinical manifestations, including primary effusion lymphoma, an aggressive CD38+ B cell lymphoma with a plasmablastic phenotype. Case This case describes an antiretroviral therapy‐adherent person with HIV who presented with concurrent KSHV‐related disorders of Kaposi ...
Kandice Roberts, Paula Valiño Ramos, Saurabh Jindal, Vikas Prasad, Yi Shan Lee, Mariam Khanfar, Obi L. Griffith, Malachi Griffith, Jeanne Jiang, Ethel Cesarman, Daniel Rauch, Paul Simonson, Thomas Odeny, Lee Ratner   +13 more
wiley   +1 more source

Sequential EBUS-Guided Fine Needle Aspiration and Transbronchial Cryobiopsy for the Diagnosis of a Giant Mediastinal Lipoma: A Novel Intraoperative Pivot Strategy. [PDF]

Respirol Case Rep
Kanchustambham V, Bowker WE.
europepmc   +1 more source

A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults

Clinical Pharmacology in Drug Development, Volume 15, Issue 6, June 2026.
Abstract Brigatinib is an ALK tyrosine kinase inhibitor approved for the treatment of adults with ALK+ non‐small cell lung cancer. The commercial formulation of brigatinib is an immediate‐release (IR) tablet; however, an oral solution was developed for use in pediatric studies for patients unable to swallow solid oral dosage forms. This randomized, two‐
Michael J. Hanley, Ronald Gounden, Bradley Hupf, Saurabh Sarkar, Robert J. Fram, Neeraj Gupta   +5 more
wiley   +1 more source

Long-Term Survival After Desperation Surgery for Primary Mediastinal Non-Seminomatous Germ Cell Tumor With Rising Alpha-Fetoprotein. [PDF]

IJU Case Rep
Aigase T, Kishida T, Kubo H, Matsumoto T, Suzuki A, Washimi K, Okubo Y, Hara S, Sugiura H, Nakaigawa N.   +9 more
europepmc   +1 more source

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach ...
Katherine Antel, Nina Xiong, Mwanasha Merrill, Taiyang Chen, Lauren McGrath, Clara Droessler, Maxine van der Schyff, Meng‐Xuan Wu, Dylan Cheddie, Charlotte Slome, Liam McBride, Jonathan Day, Zainab Mohamed, Nazia Fakie, Nomonde Mbatani, Charlotte Shultz, Graeme Meintjes, Svitlana Tyekucheva, Elizabeth F. Cohen, Michael Y. Tolstorukov, Estelle Verburgh, Mark A. Murakami   +21 more
wiley   +1 more source

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant. [PDF]

Front Pediatr
Tawil S, Deeb N, Alashwas W, Saleh H, Salami K, Jafar A.   +5 more
europepmc   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming‐Chung Wang, Wojciech Legiec, Stephen Opat, Junvie Pailden, Hillary M. Peltier, Emerenziana Marturano, James P. Dean, Ian W. Flinn   +17 more
wiley   +1 more source

Primary Mediastinal Seminoma: A Diagnostic and Therapeutic Challenge With an Optimistic Outcome. [PDF]

Case Rep Oncol Med
Dos Santos Bueno S, Borin Previtale R, Rocha Alves M, Soares Faico-Filho K.   +3 more
europepmc   +1 more source